Table 2.

Comparison of cadonilimab with nivolumab and ipilimumab: target antigen binding and competitive binding with target antigen and ligand.

Antibody	EC50 (nM) of antigen binding				EC50 (nM) of competitive binding
	aELISA		bFACS		cELISA				dFACS
	PD1-mFc	CTLA4-mFc	293 T-PD1 cell	293 T-CTLA4 cell	PD1-hFc		CTLA4-mFc		293 T-PD1 cell	293 T-CTLA4 cell
					PDL1-mFc	PDL2-His	B7.1-hFc-bio	B7.2-His	PDL1-mFc	B7.1-hFc-bio
Cadonilimab	0.051	0.079	1.812	3.09	0.792	1.429	1.052	0.718	2.62	3.93
Nivolumab	0.084	\	1.503	\	0.725	3.035	\	\	1.53	\
Ipilimumab	\	0.033	\	0.5363	\	\	1.345	0.591	\	1.64

Notes: a, fusion protein of mouse Fc with human PD-1 extracellular domain (PD1-mFc), and fusion protein of mouse Fc with human CTLA-4 extracellular domain (CTLA4-mFc) was fixed onto the plates in the assays. c, fusion protein of human Fc with human PD-1 extracellular domain (PD1-hFc), and CTLA4-mFc was fixed onto the plates; histidine-tagged human PDL-2 extracellular domain (PDL2-His) and human B7.2 extracellular domain (B7.2-His), and fusion protein of mouse Fc with human PDL1 extracellular domain (PDL1-mFc), and biotinylated fusion protein of human Fc with human B7.1 extracellular domain (B7.1-hFc-bio) were used as competition ligand in the assays. b, d, 293 T cells transfected with human PD-1 (293 T-PD1 cell) or CTLA-4 (293 T-CTLA4 cell) were used as target cells in the assay. d, PDL1-mFc and B7.1-hFc-bio were used as competition ligand in the assays.